Drug Trial Radar · NCT05792163
A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Mar 20, 2023
Primary completion
Nov 29, 2023
Study completion Nov 29, 2023
Sponsor
- Lead sponsor
- SciNeuroIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
SNP318 is developed to treat neurodegenerative diseases including Alzheimer's disease. In the current phase 1 study, the IP is tested in healthy volunteers, and the purpose is to investigate the safety, tolerability, and PK of single and multiple ascending oral doses of SNP318.
Conditions
- Neurodegenerative Diseases
- Alzheimer's Disease
Interventions
SNP318 (A)Drug
Capsule for oral administration
Placebo (B)Drug
Placebo capsules matching the SNP318 capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of SNP318 in healthy adult participants. Assessed by adverse eventsTime frame: Up to 20 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CMAX Clinical Research
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.